Avicanna Announces Change in CFO

Core Points - Avicanna Inc. has appointed Nick Hilborn as Interim Chief Financial Officer, succeeding Phillip Cardella who transitions to a consulting role [1][2] - The CEO, Aras Azadian, expressed gratitude for Cardella's contributions during transformative years and highlighted Hilborn's familiarity with the company and its culture [2] Company Overview - Avicanna is a biopharmaceutical company focused on developing, manufacturing, and commercializing plant-derived cannabinoid-based products for the global medical and pharmaceutical markets [3] - The company has a scientific platform that includes R&D and clinical development, leading to over thirty proprietary, evidence-based finished products and four commercial stage business pillars [3] Product and Service Offerings - The RHO Phyto™ formulary includes a diverse range of proprietary products with various cannabinoid ratios, available nationwide in Canada and expanding internationally [6] - MyMedi.ca is a medical cannabis care platform aimed at enhancing the patient journey, featuring a diverse product portfolio and bilingual pharmacist-led support programs [6] - Avicanna has developed a pipeline of proprietary cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [6] - The company’s subsidiary, Santa Marta Golden Hemp SAS, supplies high-quality CBD, THC, and CBG for various applications, forming part of Avicanna's supply chain [6]